Background: Psoriasis is a cutaneous inflammatory condition characterized by an altered turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic drugs inhibiting interleukin-17.
Objective: We report the first case, according to Naranjo score, of a secukinumab-induced erectile dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug (ixekizumab).
Methods: A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17. The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days.
Results: Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete skin clearance.
Conclusion: We describe for the first time a sexual dysfunction possibly due to secukinumab and its resolution after the switch to another similar but different drug, highlighting the potential difference between anti-IL17A drugs.
[http://dx.doi.org/10.1016/j.jaad.2018.02.027] [PMID: 29438757]
[http://dx.doi.org/10.1016/j.jaad.2016.03.024] [PMID: 27180926]
[http://dx.doi.org/10.1016/j.jaad.2018.01.003] [PMID: 29307635]
[http://dx.doi.org/10.1111/jdv.14391] [PMID: 28602039]